I. ACTION
New Policy 
II. POLICY DISCLAIMER
Johns Hopkins HealthCare LLC (JHHC) provides a full spectrum of health care products and services for Employer Health Programs, Priority Partners, Advantage MD and US Family Health Plan. Each line of business possesses its own unique contract and guidelines which, for benefit and payment purposes, should be consulted to know what benefits are available for reimbursement.
Specific contract benefits, guidelines or policies supersede the information outlined in this policy. 
III. POLICY

IV. POLICY CRITERIA
A. When benefits are provided under the member's contract, JHHC considers brachytherapy, (interstitial, intracavitary, or internal) to be medically necessary for ANY of the following: 
V. DEFINITIONS
Brachytherapy -is derived from ancient Greek words for 'short distance' (brachios) and 'treatment' (therapy), and refers to therapeutic use of encapsulated radionuclides within or close to a tumor. (Skowronek, 2017) .
Intracavitary Treatment -a type of brachytherapy which involves the placement of a radioactive source in the body cavity near the tumor such as the cervix, vagina, or trachea. (Mayo, 2018) .
Interstitial Treatment -a type of brachytherapy which is performed by placing the radioactive source in the form of seeds, pellets, or sheets directly into or around the tissue such as the prostate. (Mayo, 2018) .
Temporary Brachytherapy -is when the radioactive sources are removed at the end of each treatment session. The sources are often inserted using applicators such as thin plastic tubes (catheters) or cylinders. These applicators may be removed at the end of each session, or left in place until after the final session. Temporary brachytherapy is mostly used for prostate cancers and gynecological cancers (such as cervical and vaginal cancers). (Cancer Council NSW, 2017).
Permanent Brachytherapy -is when radioactive seeds about the size of an uncooked grain of rice are put inside special needles and implanted into the body. The needles are removed, and the seeds are left in place to gradually decay. As the seeds decay, they release small amounts of radiation over weeks or months. They will eventually stop releasing radiation, but they will not be removed. This is a low-dose-rate technique and it is often used to treat small prostate cancers. (Cancer Council NSW, 2017).
VI. BACKGROUND
Brachytherapy is an advanced form of radioactive treatment for cancer, particularly prostate and gynecologic cancers. In addition, brachytherapy is currently used as a treatment option for breast, head and neck, gastrointestinal (rectal/anal, biliary, esophageal), skin, lymphoma, and lung cancer. The procedure involves inserting radioactive implants/seeds directly on top of the tumor or affected tissue. Once administered, the radiation damages any cancerous cells and prohibits the cancer cells ability to replicate and grow. Patients may receive brachytherapy treatment alone or in conjunction with other therapies.
It is an internal radiation therapy that is applied either in a permanent manner (sometimes called 'seed implantation'), or in a temporary manner, often through the use of catheters, into which the radioactive sources are placed. The radioactive materials (seeds or in catheters) are placed inside the body, and positioned in such a way that will most effectively treat the disease. When permanent brachytherapy is being used, the radioactive 'seeds' are left inside the body. The half-life of the radioactive isotope used, gauges how long they will be radioactive within the body, since the radioactivity of seeds diminishes over time. Temporary brachytherapy usually involves either an in-patient procedure (low-dose-rate-brachytherapy -LDR), with the patient staying in hospital for several days, while the radioactive sources treat the disease; or in an out-patient setting (highdose-rate brachytherapy -HDR), where the patient usually undergoes several radiation treatments within a short period of time. In many centers worldwide, LDR is replaced by HDR or PDR (pulsed-dose-rate) techniques. Since in Brachytherapy the radiation source is close to or within the target volume, the dose is determined largely by inverse-square considerations. This means that the geometry of the implant is important. Spatial arrangements have been determined for different types of applications based on the particular anatomic considerations of the tumor and important normal tissues. The dose decreases rapidly, as the distance from the applicator increases. This emphasizes the importance of proper placement of applicators. (Skowronek, 2017) Brachytherapy has been proved to be very effective and safe way of treatment, providing a good alternative to surgical removal of the prostate, breast, and cervix, while reducing the risk of certain long-term side effects. (Skowronek, 2017) .
The effectiveness of brachytherapy is well-documented in medical literature. In prostate cancer, one 12-year study concluded that 66% of patients who were administered brachytherapy alone and 79% of patients who were administered external radiation in addition to brachytherapy were free of biochemical or clinical recurrence (Ragde et al, 2000) . Furthermore, one study conducted a 10-year follow up and reported negative findings in patients who received post-treatment prostate biopsies (Kuban et al, 1992 
VII. CODING DISCLAIMER
CPT Copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
Note: The following CPT/HCPCS codes are included below for informational purposes. Inclusion or exclusion of a CPT/ HCPCS code(s) below does not signify or imply member coverage or provider reimbursement. The member's specific benefit plan determines coverage and referral requirements. All inpatient admissions require preauthorization.
Compliance with the provision in this policy may be monitored and addressed through post payment data analysis and/or medical review audits
Employer Health Programs (EHP) refer to specific Summary Plan Description (SPD). If there is no criteria in the SPD, apply the Medical Policy criteria. Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; concurrent with partial mastectomy (List separately in addition to code for primary procedure)
19298 Placement of radiotherapy afterloading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following (at the time of or subsequent to) partial mastectomy, includes imaging guidance 
